OmanTuberculosis profile
Population  2015 4.5 million
Estimates of TB burden*, 2015 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.024 (0.015–0.034) 0.52 (0.33–0.76)
Mortality (HIV+TB only) <0.01 (0–<0.01) 0.01 (0–0.05)
Incidence  (includes HIV+TB) 0.38 (0.32–0.43) 8.4 (7.2–9.7)
Incidence (HIV+TB only) <0.01 (<0.01–<0.01) 0.08 (0.07–0.1)
Incidence (MDR/RR-TB)** 0.015 (<0.01–0.024) 0.33 (0.13–0.53)
Estimated TB incidence by age and sex (thousands)*, 2015
  0-14 years > 14 years Total
Females 0.013 (<0.01–0.019) 0.15 (0.11–0.19) 0.16 (0.12–0.21)
Males 0.013 (<0.01–0.017) 0.2 (0.16–0.24) 0.21 (0.17–0.26)
Total 0.026 (0.019–0.033) 0.35 (0.32–0.38) 0.38 (0.32–0.43)
TB case notifications, 2015  
Total cases notified 328
Total new and relapse 328
          - % tested with rapid diagnostics at time of diagnosis 100%
          - % with known HIV status 100%
          - % pulmonary 67%
          - % bacteriologically confirmed among pulmonary 100%
Universal health coverage and social protection  
TB treatment coverage (notified/estimated incidence), 2015 87% (75–100)
TB patients facing catastrophic total costs  
TB case fatality ratio (estimated mortality/estimated incidence), 2015 0.06 (0.04–0.1)
TB/HIV care in new and relapse TB patients, 2015 Number (%)
Patients with known HIV-status who are HIV-positive 4 1%
          - on antiretroviral therapy 4 100%
Drug-resistant TB care, 2015 New cases Previously treated
cases
Total
number***
Estimated MDR/RR-TB cases among notified
pulmonary TB cases
  7
(2–12)
Estimated % of TB cases with MDR/RR-TB 3.5% (1.5–6.7) 0% (0–37)  
% notified tested for rifampicin resistance 79% 100% 260
MDR/RR-TB cases tested for resistance to second-line drugs   3
Laboratory-confirmed cases MDR/RR-TB: 3, XDR-TB: 0
Patients started on treatment **** MDR/RR-TB: 3, XDR-TB: 0
Treatment success rate and cohort size Success Cohort
New and relapse cases registered in 2014 96% 358
Previously treated cases, excluding relapse, registered in 2014   0
HIV-positive TB cases, all types, registered in 2014 100% 3
MDR/RR-TB cases started on second-line treatment in 2013 100% 2
XDR-TB cases started on second-line treatment in 2013   0
TB preventive treatment, 2015  
% of HIV-positive people (newly enrolled in care) on preventive treatment  
% of children (aged < 5) household contacts of bacteriologically-confirmed
TB cases on preventive treatment
100% (100–100)
TB financing, 2016  
National TB budget (US$ millions)  
* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Includes cases with unknown previous TB treatment history
**** Includes patients diagnosed before 2015 and patients who were not laboratory-confirmed
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population per year)
Incidence graph
   Incidence
   Notified (new and relapse)
   Incidence (HIV+TB only)

Notified cases by age group and sex, 2015
age_sex_graph
____
FemalesMales

Treatment success rate (%)
tx success graph
   
New and relapse
   Retreatment, excluding relapse
   HIV-positive   MDR/RR-TB   XDR-TB

 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2016-12-08 Data: www.who.int/tb/data